title: Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
abstract: Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases. Experimental and clinical evidence suggests beneficial effects of AVP receptor antagonists by increasing free water excretion and serum sodium levels. This review provides an update on the therapeutic implication of newly developed AVP receptor antagonists in respective disorders, such as chronic heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion.
authors.affiliation: Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
authors.forename: Natig
authors.initials: N
authors.lastname: Gassanov
authors.affiliation: Department of Medicine II, University Hospital Freiburg, Freiburg, Germany.
authors.forename: Nasser
authors.initials: N
authors.lastname: Semmo
authors.affiliation: Department of Nephrology, University Hospital Freiburg, Freiburg, Germany.
authors.forename: Mariam
authors.initials: M
authors.lastname: Semmo
authors.affiliation: Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
authors.forename: Amir M
authors.initials: AM
authors.lastname: Nia
authors.affiliation: Department of Pharmacology, University of Cologne, Cologne, Germany.
authors.forename: Uwe
authors.initials: U
authors.lastname: Fuhr
authors.affiliation: Department of Internal Medicine III, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. fikret.er@uk-koeln.de.
authors.forename: Fikret
authors.initials: F
authors.lastname: Er
mesh_terms: D065092:Antidiuretic Hormone Receptor Antagonists; D001549:Benzamides / Q000494:pharmacology / Q000627:therapeutic use; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007177:Inappropriate ADH Syndrome / Q000188:drug therapy* / Q000378:metabolism; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000378:metabolism; D008954:Models, Biological; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use; D013141:Spiro Compounds / Q000494:pharmacology / Q000627:therapeutic use; D000077602:Tolvaptan; D014882:Water-Electrolyte Balance / Q000187:drug effects / Q000502:physiology; D001569:Benzodiazepines
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001549:Benzamides; D001552:Benzazepines; D004232:Diuretics; D009025:Morpholines; D011758:Pyrroles; D013141:Spiro Compounds; D000077602:Tolvaptan; C106389:conivaptan; C409452:lixivaptan; D001569:Benzodiazepines; C103281:satavaptan